Neuren Pharmaceuticals
NEU.AX
#4834
Rank
HK$16.04 B
Marketcap
HK$126.53
Share price
-0.09%
Change (1 day)
31.93%
Change (1 year)

P/E ratio for Neuren Pharmaceuticals (NEU.AX)

P/E ratio at the end of 2025: 81.3

According to Neuren Pharmaceuticals's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 101.511. At the end of 2025 the company had a P/E ratio of 81.3.

P/E ratio history for Neuren Pharmaceuticals from 2005 to 2025

PE ratio at the end of each year

Year P/E ratio Change
202581.3554.66%
202412.4-38.67%
202320.2-99.62%
2022> 1000-9984.94%
2021-54.1305.46%
2020-13.3-40.75%
2019-22.5-151.16%
201844.0-128.82%
2017-1531835.42%
2016-7.90-41.75%
2015-13.6-28.67%
2014-19.097.42%
2013-9.6378.92%
2012-5.3881.44%
2011-2.97248.05%
2010-0.8520-101.2%
200970.7-48701.45%
2008-0.1455-90.93%
2007-1.61-58.92%
2006-3.91-34.95%
2005-6.01

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.